QDX
June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
QDX is a drug discovery company specializing in high-performance quantum simulations to accelerate the design of new therapeutics. Founded by experts in life science, computational chemistry, and high-performance computing, QDX collaborates with global partners to develop innovative solutions for complex diseases, aiming to transform the landscape of drug discovery. Its flagship platform, Rush, empowers biotech innovators to conduct fast, cost-effective molecular modeling, virtual screening, and predictive analytics—no installation or proprietary hardware required.
Company HQ City:
Singapore
Company HQ State:
Singapore
Company HQ Country:
Singapore
Year Founded:
2023
Lead Product in Development:
Rush is a cloud-native, AI-quantum drug discovery platform designed to drastically improve the speed, accuracy, and cost-efficiency of early-stage therapeutic development. It integrates:
- Ab initio quantum chemistry simulations at unprecedented scale (exascale-ready)
- AI-driven predictive analytics for molecular property prediction, screening, and design
- High-performance computing that operates fully in the cloud—no proprietary hardware required
- Autonomous drug discovery workflows
Rush enables biotech companies, research institutions, and pharmaceutical partners to perform:
- Molecular modeling
- Virtual screening
- Lead optimization
- Binding affinity prediction
… all without the usual hardware, setup, or scale limitations.
CEO
Loong Wang
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
NA. However we are seeking users for the Rush platform, as well as collaborators for bespoke drug discovery projects.
When you expect your next catalyst update?
Our next key catalyst will be either closing a dedicated fundraise to scale Rush, or successfully onboarding 1,000 researchers and 1,000 startups onto the platform. We see both as equally meaningful inflection points in validating Rush’s potential to democratize quantum-powered drug discovery. These milestones will accelerate our mission to make high-performance computational tools radically accessible—removing barriers for innovators working on the next generation of therapeutics.
What is your next catalyst (value inflection) update?
Dec 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}